PERCEPTIVE ADVISORS LLC

Average Profitability
<0.0001%
Insider Buys Quantity
116
Insider Buys Sum
$836.97M
Insider Sells Quantity
22
Insider Sells Sum
$33.75M

Insider Activity of PERCEPTIVE ADVISORS LLC

According to the SEC Form 4 filings, PERCEPTIVE ADVISORS LLC, being in a position of

  1. 10 percent owner at Acrivon Therapeutics, Inc. Common Stock,
    Đľver the last 12 months, has bought 2353000 shares for $20M, and sold 0 shares,
    over all time since 2024-04-11, has bought 2353000 shares for $20M, and sold 0 shares.

The largest purchase of all time was on 2021-06-09 and amounted to 5500000 shares of Nautilus Biotechnology, Inc. for $55M.

The largest sale of all time was on 2016-08-25 and amounted to 2200000 shares of Amicus Therapeutics, Inc. for $14.98M.

Biography of PERCEPTIVE ADVISORS LLC

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$47,918,8728100
Sells
$000

Comparison of Insiders on Amount of Buys and Sells

2025-02-19PurchaseSolid Biosciences Inc.
SLDB
5M
9.5155%
$4.03$20.15M-8.74%
2024-08-12PurchaseMeiraGTx Holdings plc
MGTX
1.25M
1.9341%
$4.00$5M+52.25%
2024-04-11PurchaseAcrivon Therapeutics, Inc. Common Stock
ACRV
10 percent owner
2.35M
8.4743%
$8.50$20M-21.1%
2024-04-05PurchaseAldeyra Therapeutics, Inc.
ALDX
10 percent owner
37,712
0.0643%
$4.74$178,755+5.08%
2024-04-04PurchaseAldeyra Therapeutics, Inc.
ALDX
10 percent owner
140,281
0.2374%
$4.67$655,112+5.88%
2024-04-03PurchaseAldeyra Therapeutics, Inc.
ALDX
10 percent owner
309,847
0.5185%
$4.09$1.27M+19.28%
2024-04-02PurchaseAldeyra Therapeutics, Inc.
ALDX
10 percent owner
186,051
0.3061%
$3.44$640,015+39.3%
2024-04-01PurchaseAldeyra Therapeutics, Inc.
ALDX
10 percent owner
8,374
0.0141%
$3.25$27,216+51.07%
2024-02-01PurchaseAstria Therapeutics, Inc.
ATXS
director
2.48M
5.6893%
$12.09$30M-19.99%
2024-01-11PurchaseSolid Biosciences Inc.
SLDB
3.41M
12.2033%
$5.53$18.86M+1.75%
2023-12-29PurchaseAthira Pharma, Inc.
ATHA
163,954
0.4272%
$2.38$390,211+3.7%
2023-12-29PurchaseVerrica Pharmaceuticals Inc.
VRCA
10 percent owner
115,774
0.2752%
$7.24$838,204-27.94%
2023-12-28PurchaseAthira Pharma, Inc.
ATHA
409,598
1.0852%
$2.44$999,419+2.44%
2023-12-28PurchaseVerrica Pharmaceuticals Inc.
VRCA
10 percent owner
126,116
0.2934%
$7.08$892,901-27.57%
2023-12-27PurchaseAthira Pharma, Inc.
ATHA
32,134
0.0833%
$2.28$73,266+9.09%
2023-12-27PurchaseVerrica Pharmaceuticals Inc.
VRCA
10 percent owner
79,726
0.1901%
$7.20$574,027-25.87%
2023-12-26PurchaseVerrica Pharmaceuticals Inc.
VRCA
10 percent owner
54,652
0.1301%
$6.49$354,691-17.85%
2023-12-22PurchaseVerrica Pharmaceuticals Inc.
VRCA
10 percent owner
250,000
0.5943%
$6.67$1.67M-20.45%
2023-12-21PurchaseAstria Therapeutics, Inc.
ATXS
director
740,000
2.0257%
$6.20$4.59M+77.37%
2023-12-21PurchaseVerrica Pharmaceuticals Inc.
VRCA
10 percent owner
200,000
0.4555%
$6.17$1.23M-14.98%
Total: 138
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Sells over the last 12 months, USD